 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Aphton Corporation
 |
Aphton Corporation |
 |
 |
 |
PROFILE |
 |
Aphton says, "Just block it!" The development-stage biopharmaceutical company is researching and testing immunogen-based drugs for the treatment of gastrointestinal and reproductive-system ailments. The drugs neutralize or block hormones that play a key role in such diseases as stomach, liver, pancreatic, prostate, breast, and endometrian cancers, as well as stomach ulcers. Aphton's drug development partners include Aventis for an anti-gastrin vaccine to combat gastrointestinal cancers and the World Health Organization for the clinical development of an immuno-contraceptive.
COMPETITION |
 |
AVAX Technologies, Inc. (AVXT)
Cephalon, Inc. (CEPH)
Kosan Biosciences Incorporated (KOSN)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: January
2001 Sales (mil.): 0.10
1-Yr. Sales Growth: 0.0%
Employees: 40
Revenue per employee: $2,500.00
KEY PEOPLE |
 |
Philip C. Gevas
CEO
Frederick W. Jacobs
CFO
CONTACT INFO |
 |
444 Brickell Ave., Ste. 51-507
Miami, FL 33131
US
Phone: 305-374-7338
Fax: 305-374-7615
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |